Business Wire

HUBILO

2.2.2021 16:20:05 CET | Business Wire | Press release

Share
Event Technology Platform Hubilo Integrates Multilingual Feature for the European Market

Event technology company Hubilo has updated its virtual event platform to include support for all the European languages, to meet the demands of a growing global market for virtual events which is expected to be worth over $400bn by 2027.

Hubilo’s platform offers customers a DIY (Do It Yourself) feature that allows them to create events based on individual specifications using a few basic steps, including customizing events in their chosen language to make the entire process simple to understand and operate. The new multilingual feature enables Hubilo to support customers across Europe better, creating a truly universal hub.

Additional Features include a networking lounge where attendees can connect and video chat with the ones with similar interests, virtual booths that provide businesses and promoters with a separate online space to market their products, speaker lounges where attendees can see a list of all event speakers and their sessions and register and add sessions to their event itinerary, live and on-demand sessions, surveys and polls , gamification experiences , automated registrations and ticket processes, and 24/7 customer care services.

For the organizers, there is a provision of features like analytics and insights to help them with quality lead assessments for conversions, a system of records that acts as a reference point to ensure that the organizers have a complete understanding of the attendee engagement rate and interactions along with other required insights across various touchpoints at the event, a broadcast studio which eliminates the need of an additional video conference software, at the same time shares all the tools that are provided by the external software and branded themes , here you can customize your event as per your brand guideline to deliver the precise brand messaging.

Vaibhav Jain, Founder and CEO, Hubilo said: “We launched our virtual platform to deliver a richer online experience for organizers and attendees, mirroring numerous positive features of in-person events along with the addition of a few advanced ones. We are glad that we are able to offer a more inclusive range of languages to our existing, and new as well as prospective clients across Europe. In fact, in order to comply with the European rules and regulations, Hubilo will also now host information on European clients and attendees on dedicated EU servers, within the European jurisdiction.”

Hubilo, which lists Roche, GITEX and Informa Group among its customers, managed to pivot to deliver online virtual events in February 2020, backed by a $4.5m investment led by Lightspeed Venture Partners. Hubilo covers the entire spectrum of meetings, incentives, conferences, and exhibitions (MICE) for external and internal events such as trade fairs, job fairs, award shows, annual sales meet, employee engagement initiatives, town halls, office parties and more.

About Hubilo :

Event technology Company Hubilo has created a comprehensive virtual platform that meets all the event-based requirements through the integration of numerous technology tools. They have redefined the entire marketing landscape around virtual events to unlock massive value for key stakeholders, such as CMOs, event organizers, and sponsors. Hubilo covers the entire spectrum of meetings, incentives, conferences and exhibitions (MICE) which include FMCG, BFSI, Education, Healthcare and Pharmaceutical, Information Technology and Manufacturing, as well as several other industries. Founded in 2015 and pivoted in February 2020 by Vaibhav Jain and Mayank Agarwal, in just 5 years, Hubilo's clientele is inclusive of names like United Nations, Roche, Informa Markets, Tech in Asia, Fortune, AWS, Siemens, GITEX, to name a few.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye